Szabo Gyongyi, Petrasek Jan
Department of Medicine, University of Massachusetts Medical School, LRB 215, 364 Plantation Street, Worcester, MA 01605,USA.
Department of Medicine, University of Massachusetts Medical School, LRB 215, 364 Plantation Street, Worcester, MA 01605, USA.
Alcohol Alcohol. 2017 Jul 1;52(4):414-424. doi: 10.1093/alcalc/agx025.
Innate immunity plays a critical role in the development of alcohol-induced liver inflammation. Understanding the inter-relationship of signals from within and outside of the liver that trigger liver inflammation is pivotal for development of novel therapeutic targets of alcoholic liver disease (ALD).
The aim of this paper is to review recent advances in the field of alcohol-induced liver inflammation.
A detailed literature review was performed using the PubMed database published between January 1980 and December 2016.
We provide an update on the role of intestinal microbiome, metabolome and the gut-liver axis in ALD, discuss the growing body of evidence on the diversity of liver macrophages and their differential contribution to alcohol-induced liver inflammation, and highlight the crucial role of inflammasomes in integration of inflammatory signals in ALD. Studies to date have identified a multitude of new therapeutic targets, some of which are currently being tested in patients with severe alcoholic hepatitis. These treatments aim to strengthen the intestinal barrier, ameliorate liver inflammation and augment hepatocyte regeneration.
Given the complexity of inflammation in ALD, multiple pathobiological mechanisms may need to be targeted at the same time as it seems unlikely that there is a single dominant pathogenic pathway in ALD that would be easily targeted using a single target drug approach.
Here, we focus on recent advances in immunopathogenesis of alcoholic liver disease (ALD), including gut-liver axis, hepatic macrophage activation, sterile inflammation and synergy between bacterial and sterile signals. We propose a multiple parallel hit model of inflammation in ALD and discuss its implications for clinical trials in alcoholic hepatitis.
固有免疫在酒精性肝炎症的发展中起关键作用。了解触发肝脏炎症的肝脏内外信号之间的相互关系对于开发酒精性肝病(ALD)的新型治疗靶点至关重要。
本文旨在综述酒精性肝炎症领域的最新进展。
使用1980年1月至2016年12月期间发表的PubMed数据库进行了详细的文献综述。
我们提供了关于肠道微生物组、代谢组和肠-肝轴在ALD中的作用的最新信息,讨论了关于肝脏巨噬细胞多样性及其对酒精性肝炎症的不同贡献的越来越多的证据,并强调了炎性小体在ALD炎症信号整合中的关键作用。迄今为止的研究已经确定了许多新的治疗靶点,其中一些目前正在重症酒精性肝炎患者中进行测试。这些治疗旨在加强肠道屏障、改善肝脏炎症和促进肝细胞再生。
鉴于ALD炎症的复杂性,可能需要同时针对多种病理生物学机制,因为似乎不太可能存在单一的主导致病途径,而单一靶点药物方法可以轻易针对该途径。
在这里,我们关注酒精性肝病(ALD)免疫发病机制的最新进展,包括肠-肝轴、肝巨噬细胞活化、无菌炎症以及细菌和无菌信号之间的协同作用。我们提出了ALD炎症的多平行打击模型,并讨论了其对酒精性肝炎临床试验的意义。